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Introduction
Asthma belongs to the most common respiratory diseases 
affecting 5% to 8% of the Swiss population (1). Asthma 
is an obstructive respiratory disease characterized by 
chronic inflammation of the airways with airway hyper-
responsiveness, recurrent symptoms and exacerbations that 
vary over time and in intensity, and typically reversible 
expiratory airflow limitation (2). As recommended in the 
guidelines of the Global Initiative for Asthma, the goal of 
asthma treatment is to achieve asthma control, i.e., to control 
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symptoms and risk factors for future poor outcomes (2). 
Inhaled administration of pharmaceutically active substances 
is the preferred route because it optimizes drug delivery 
directly to the airways as well as tolerability by minimizing 
systemic exposure. However, the capability of using the 
inhaler device appropriately is often insufficient, even in 
experienced outpatients (3,4), and is associated with poorer 
disease control and increased use of healthcare resources (5).
Proper inhaler technique is crucial for effective 
management of asthma and results from the complex 
interaction between the health care professionals, the 
therapy itself [i.e., the drug(s) and the inhaler device], and 
the patient in his environment. Health care professionals 
should ensure that the patient has acquired and maintains a 
correct inhaler technique over time (6,7). Patient education 
provided by health care professionals (physicians, but also 
pharmacists or nurses) with regard to the disease and to 
handling of the device has repeatedly been shown to be 
of crucial importance (8-10). While drug choice is usually 
the first step when prescribing an inhaled therapy, some 
have argued that choice of the inhaler device may be even 
more important (11,12). The available inhaler devices share 
common potential sources of handling errors. In addition, 
pressurized metered-dose inhalers (pMDI) and dry-powder 
inhalers (DPI) have specific requirements that may lead 
to additional errors in daily practice (7,13,14). Finally, 
the patient should ultimately be adherent and compliant 
with the prescribed therapy, which can be best achieved 
through better understanding of his medical history and 
comorbidities, cultural environment, health behaviors, and 
preferences (15).
The aim of the Asthma Survey was to generate insights 
about the daily practice of physicians with regard to 
inhaler devices used for treating asthma, under real-world 
conditions in Switzerland. 
Methods
A questionnaire was designed and administered as 1:1 
interviews to hospital- and practice-based Swiss physicians 
willing to participate by well-trained representatives 
of a pharmaceutical company operating in the field of 
obstructive respiratory diseases (Mundipharma Medical 
Company, Basel, Switzerland). All participating physicians 
were listed in the Swiss register of practicing physicians of 
the Swiss Medical Association (FMH) used by the sponsor 
(www.doctorfmh.ch). As shown in the Supplementary, in 
addition to physician demographics [age, specialty, canton 
of practice, and prescriber status (self-dispensing or not)], 
the predefined areas of interest were (I) aspects of patient 
education regarding the use of an inhaler device (three 
questions); (II) typical difficulties encountered in daily 
practice when prescribing a pMDI and DPI (two questions); 
(III) behaviors and real-world reasons for physician 
preferences in daily practice (four questions). 
For the purpose of statistical analysis, descriptive 
methods were used. All physicians with known place of 
practice were included in the analysis. For unprompted 
answers (free text), category headings were defined post 
hoc and adjudication performed by an informed physician. 
In the primary analysis, overall means with corresponding 
standard deviations or medians with interquartile ranges 
were calculated for normally and non-normally distributed 
variables, respectively. In a secondary analysis, differences 
between linguistic regions [German-speaking part of 
Switzerland (D-CH) and French- and Italian-speaking parts 
of Switzerland (W-CH) parts of Switzerland] were tested 
for statistical significance by exploratory chi-square tests and 
by calculating exploratory odds-ratios with corresponding 
95% confidence intervals using the statistical software 
SPSS version 19.1. A P value below 0.05 was considered 
statistically significant. 
The survey was performed in accordance with the 
Helsinki Declaration as revised in 2013. Formal Ethical 
Review Committee approval was not necessary per written 
declaration of no ethical impediment Nb. 77-2015 of the 
cantonal ethical commission of Zurich, Switzerland.
Results
Data collection occurred between April 2014 and August 
2015. In total, 605 physicians accepted to participate. 
Of these, 529 (87.4%) provided datasets suitable for 
analysis, 291 (55.0%) in the D-CH and 238 (45.0%) in 
the W-CH part of Switzerland. The final dataset included 
questionnaires from 342 internists/general practitioners 
(190 and 152 in D-CH and W-CH, respectively), 177 
pulmonologists/allergologists (95 and 82), and 10 other 
(6 and 4). The response rate was 34.8% and 6.2% of 
all hospital- or private practice-based pulmonologists/
allergologists and general practitioners/internists in 
Switzerland, respectively. Self-dispensing physicians 
represented 56.0% of all included in D-CH and prescribing 
physicians 90.3% of all included in W-CH. 
When a  new f ixed  combinat ion of  an  inhaled 
corticosteroid (ICS) and long-acting beta-agonist (LABA) 
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was prescribed to a patient with asthma, prior therapy was 
either another ICS + LABA (49.1%), a short acting beta-
agonist (SABA, 38.1%), an ICS monotherapy (20.7%) or a 
leukotriene receptor antagonist (LTRA, 8.3%) with multiple 
answers allowed. A direct switch from a SABA to a fixed 
ICS + LABA combination was significantly more likely to 
occur in D-CH compared to W-CH (44.2% vs. 30.7%; OR 
=1.7; 95% CI, 1.1–2.5; P=0.007). Conversely, a switch from 
another ICS + LABA was significantly less likely to occur 
in D-CH (39.9% vs. 60.2%; OR =0.4; 95% CI, 0.3–0.6; 
P<0.001).
DPI devices were overwhelmingly preferred over pMDI, 
with 83.8% of the physicians prescribing DPI to 40% or 
more of their patients. At the extremes, when considering 
the inhaler type prescribed to more than 80% of their 
patients, 35.6% of the physicians favored a DPI and only 
4.3% a pMDI (P<0.001). Interestingly, the prescription 
pattern was different between regions, with significantly 
more pMDIs prescribed in W-CH than in D-CH (Figure 1). 
The main cited reasons for prescribing a pMDI were ease of 
use (18.7%), patient demand (17.7%), expected better drug 
deposition (17.1%), less side-effects (10.2%), patient age 
(9.0%), “patient-friendliness” (8.3%), and low inspiratory 
flow requirement (7.6%). As shown in Figure 2, ease of 
use and patient demand were significant drivers of pMDI 
preference in W-CH while patient age, patient-friendliness, 
Figure 1 Proportion of patients with obstructive respiratory disease treated with a pMDI or a DPI. D-CH, German-speaking part of 
Switzerland; W-CH, French- and Italian-speaking parts of Switzerland; pMDI, pressurized metered-dose inhaler; DPI, dry-powder inhaler.
Figure 2 Main reasons for prescribing a pMDI with a statistically significant difference between linguistic regions. D-CH, German-speaking 
part of Switzerland; W-CH, French- and Italian-speaking parts of Switzerland; pMDI, pressurized metered-dose inhaler; OR, odds ratio.
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and low inspiratory flow were considered more important 
in D-CH.
The most common errors (occurring frequently or 
occasionally) encountered in daily practice when using a 
DPI were an insufficiently forceful inhalation (88.8%), 
insufficient breath-holding after inhalation (83.2%), 
and the absence of expiration before inhalation (80.9%). 
Additional errors occurred with device actuation (59.2%) 
and through expiration in the actuated device (43.7%). The 
most common errors reported when using a pMDI were 
poor coordination between device actuation and inhalation 
(90.5%), insufficient breath-holding after inhalation 
(79.6%), the absence of expiration before inhalation 
(76.2%). Additional errors were related to excessively 
fast inhalation (75.4%) and to wrong device actuation 
(39.3%). Differences between regions were not statistically 
significant.
As shown in Table 1, approximately 90% of all Swiss 
physicians declared being personally involved in educating 
their asthma patients using an inhaler device (88.3% 
vs. 92.0% in D-CH and W-CH, respectively). Of those 
who implemented patient education and inhaler training 
themselves (n=475), most made usage of a second education 
layer by either handing out a descriptive flyer (31.2%), 
requesting additional training by their practice assistant 
(17.5%), recommending to read the package insert (16.4%), 
directing the patient to the pharmacist for training (12.0%) 
or indicating other external resources such as a Web link 
(4.6%). The physicians who did not educate their patients 
themselves (n=54), delegated inhaler training to either their 
practice assistant (64.8%) or the pharmacist (18.5%) and/
or distributed a handout (29.6%) or recommended reading 
the package insert (20.4%). Only 7.4% did not implement 
any patient education measures. Differences between 
regions were not statistically significant, with the exception 
of involving the practice assistant (more frequent in D-CH, 
33.0% vs. 9.2%; OR =4.8; 95% CI, 2.9–8.0; P<0.001) and 
involving the pharmacist (less frequent in D-CH, 6.9% vs. 
19.7%; OR =0.3; 95% CI, 0.2–0.5; P<0.001). 
Patient skills with regard to inhalation technique and 
effective inhaler handling were generally not monitored on 
a regular basis (Figure 3). Only 34.0% of all participating 
physicians declared systematically checking inhalation 
technique at the next visit(s), i.e., 3 weeks (median 
value, IQR 2 to 4 weeks) after the first prescription or a 
prescription change and every 12 weeks thereafter (IQR 
8 to 24). Half of the physicians (49.3%) declared never 
controlling the inhalation technique or only in cases in 
which therapy was unsuccessful. An additional 16.7% 
eluded the question. Differences across regions were not 
statistically significant.
Physicians were generally satisfied with the patient 
education tools at their disposal with 41.3% stating that 
they were missing nothing. However, some requested an 
improved access to demonstration devices (24.6%) and to 
didactic materials for patients (17.7%). Inhalation control 
systems, spacers, and single usage nozzles were considered 
missing by less than 5% of the physicians.
Finally, in this Asthma Survey, an average (mean ± SD) of 
18 patients with any form of obstructive respiratory disease 
Table 1 Which of these practical aspects do you consider when prescribing an inhaled anti-asthmatic drug?
Physicians’ responses Total CH (%) D-CH (%) W-CH (%) OR (95% CI) P value
Participating physicians (n) 529 291 238
I train with my patient in my office 475 (89.8) 257 (88.3) 218 (91.6) 0.69 (0.39–1.24) 0.215
I hand out a flyer 164 (31.0) 90 (30.9) 74 (31.1) 0.99 (0.69–1.44) 0.968
My practice assistant trains the patient 118 (22.3) 96 (33.0) 22 (9.2) 4.83 (2.92–7.99) <0.001
I recommend reading the package insert 89 (16.8) 52 (17.9) 37 (15.5) 1.18 (0.75–1.88) 0.477
I write a note on the prescription (training by the pharmacist) 67 (12.7) 20 (6.9) 47 (19.7) 0.30 (0.17–0.52) <0.001
I indicate a link to a patient education video on the Internet 20 (3.8) 15 (5.2) 5 (2.1) 2.53 (0.91–7.07) 0.067
Other 3 (0.6) 2 (0.7) 1 (0.4) 0.684 (0.15–18.20) 0.684
None 4 (0.8) 0 (0.0) 4 (1.7) n.a. n.a.
D-CH, German-speaking part of Switzerland; W-CH, French- and Italian-speaking parts of Switzerland; OR, odds ratio.
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were seen per physician per week, of which 6.4±7.4 (35.7%) 
with asthma, 7.7±7.8 (42.5%) with chronic obstructive 
pulmonary disease (COPD), and 3.9±3.9 (21.8%) with 
ACOS. Differences between linguistic regions were not 
statistically significant.
Discussion
The Asthma Survey explored the level of education and 
inhaler training among physicians treating patients with 
asthma in Switzerland under real-world conditions of 
daily practice. Patient education seems widely accepted 
and implemented with strong involvement of the treating 
physician and regional differences in the roles of specific 
stakeholders. On the other hand, the monitoring over time 
of patient skills regarding appropriate use of their inhaler 
device has not become a generally implemented routine 
yet, indicating room for improvement in both regions. 
Within a context of clear preference for DPI devices in 
both regions, a surprising finding was that pMDIs were 
used more frequently in W-CH than in D-CH and that the 
reasons for preference differed by region. Finally, direct 
switches from SABA to a fixed combination of ICS+LABA, 
which constitute a deviation from the stepwise treatment 
approach recommended by GINA, were more frequent 
in D-CH. Overall, these findings indicate that within the 
same country, subtle differences in perceptions exist which 
may be relevant and should be further explored before 
considering the nationwide implementation of physician 
and patient education programs in the field of chronic 
respiratory diseases.
While more than 90% of the physicians declared being 
personally involved in educating their asthma patients, 
it should be remembered that an earlier Swiss survey 
involving 281 general practitioners and 1,893 patients with 
follow-up visits who undertook the Juniper Asthma Control 
Questionnaire, showed that only 16% were effectively 
controlled with a clear gap between the physician perceived 
level of asthma control and the objective measure (16). 
Furthermore, in another Swiss survey performed in the 
region of Zurich, Switzerland, only 24% of the participating 
physicians provided their patients with written action 
plans for self-management as recommended by the GINA 
guidelines (17). It is reasonable to assume that the high 
declared level of good will and personal involvement, 
which acknowledges the high perceived need for patient 
education, may suffer from the time constraints imposed to 
daily practice and contrast with achieved results. It is also 
likely that Swiss physicians almost systematically add the 
second layer of patient education/information reported in 
this survey as an anticipatory response to this perceived lack 
of efficiency. It has been repeatedly shown that health care 
providers (across all disciplines) often do not sufficiently 
master the inhalation technique themselves (7,11,18,19) 
and are not sufficiently aware of device-specific handling 
difficulties, even more so in an increasingly complex 
environment with a steadily growing inhaler diversity 
(11,13,20-22). In this context, the best person to provide 
inhaler training should be the one with the appropriate 
skills, adequate time, and access to teaching resources. 
This may be the physician himself or his practice assistant 
(as exemplified in D-CH) or the pharmacist (in W-CH). 
Figure 3 Verification by the physician of the technical appropriateness of the patients’ inhalation technique. D-CH, German-speaking part 
of Switzerland; W-CH, French- and Italian-speaking parts of Switzerland.
N=529
P
hy
si
ci
an
s 
(in
 %
)
60.0
40.0
20.0
0.0
D-CH
W-CH
Never or only if therapy 
should not be successful
No answerAt the next consultation
3101Journal of Thoracic Disease, Vol 8, No 11 November 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(11):3096-3104jtd.amegroups.com
The regional difference in terms of educational resources 
involved may be related to the fact that most participating 
physicians in D-CH were self-dispensing, while most in 
W-CH were prescribing, which arguably increases the 
intensity level of interaction with the pharmacist. 
In this Asthma Survey, only approximately one third 
of the physicians controlled inhaling skills and repeated 
the instructions at each follow-up visit, with virtually no 
difference between regions. This is of major concern. It has 
been shown that even patients who initially learned to use 
their inhaler device properly did not maintain the correct 
inhalation technique over time (7,23). It has also been 
shown that while verbal instruction combined with physical 
demonstration is the most effective training technique for 
correct inhaler use (7,23,24), only repeating this education 
does prevent drifts and increase the proportion of patients 
maintaining a correct inhalation technique over time 
(6,9). Internet-based tutorials for patients and physicians 
should be considered interesting complementary but not 
substitutive information sources in this regard (25,26). 
Thus, continuous medical education should focus on 
“training the trainer” regarding inhaler-specific knowledge 
and hands-on skills. It should also insist on the importance 
of requiring patients to demonstrate their inhaler technique 
at each follow-up visit. 
Despite the fact that all aerosol drug delivery devices 
were shown in a systematic review to be equally efficacious 
in terms of outcomes, provided that they were used 
appropriately (27), a wide diversity in inhaler prescription 
exists between European countries (28). In years 2002–2008, 
pMDIs constituted over 70% of the inhalation devices sold 
in UK whereas they represented only approximately 10% in 
Sweden, with differences possibly related to differing health 
policies, costs, commercial aspects as well as prescribers' 
and patients' preferences (28). Based on the findings in this 
survey, Switzerland clearly is a country in which physicians 
prefer to prescribe DPIs. Interestingly, the occurrence 
of general inhaler handling errors (absence of expiration 
before inhalation and insufficient breath-holding after 
inspiration) was similarly high with both DPI and pMDI. 
The nature of DPI- and pMDI specific errors was different 
(typically too slow and insufficiently forceful inhalation with 
DPI and poor coordination and too fast inhalation with 
pMDI) but of similar order of magnitude, approximating 
80–90% which is consistent with earlier findings showing 
that in the real-world at least some handling errors occur 
in 80% of the patients (20). In addition, no statistically 
significant difference in these error profiles existed across 
regions. Nevertheless, pMDI were used significantly 
more frequently in W-CH than in D-CH. Although 
this preference is consistent with a slightly higher use of 
pMDI in France than in in Germany (28), the reasons 
for this difference remain speculative. On one hand, in 
W-CH, ease of use and patient demand were significantly 
more important reasons for prescribing a pMDI than in 
D-CH. The fact that rescue asthma medication (SABA) is 
generally formulated as a pMDI may have been perceived 
as a contribution to the ease of use of pMDI in general, 
capitalizing on already trained and hopefully mastered 
skills. This is consistent with the recommendation not to 
switch between different inhalers, as each inhaler class and 
brand has its own unique requirements regarding handling 
and inhalation technique (29-31). In addition, patients do 
express preference for particular inhaler devices, which 
makes successful teaching easier (32,33). On the other 
hand, in D-CH, pMDI prescriptions were significantly 
more often triggered by patient age and by the presence of 
a low inspiratory flow than in W-CH, which is consistent 
with more technically objective reasons for prescribing and 
with the recommendation that choice of device should be 
based on the individual patient’s natural inhaler technique, 
preferring an MDI in patients who naturally tend to breathe 
in slowly and preferring a DPI in those who tend to inspire 
hard and fast (7,11). The Swiss healthcare system is identical 
in all linguistic regions, basically consisting of a compulsory 
health insurance which covers all costs related diagnostic 
and therapeutic measures, including for all chronic airway 
diseases. Differences between regions are therefore unlikely 
to be related to the healthcare system itself. It can be 
hypothesized that they may relate to human factors such 
as physician training (with two University Hospitals in the 
French-speaking part and three in the German-speaking 
part), patient preference, and last but maybe not least, the 
individual performance of sales representatives (who by 
nature differ by linguistic region). 
It should be remembered that “the ideal inhaler does not 
exist in real life” (34). An ERS/ISAM consensus statement 
provided clear guidance for choosing the most appropriate 
aerosol delivery device based on a patient’s actuation-
inhalation coordination skills and level of inspiratory flow, 
among other clinical conditions (22,34). The correct use of 
a pDMI requires adequate coordination between actuation 
of the device and inhalation (or the use of a spacer) which 
has been rendered obsolete with DPIs (3). With the ultimate 
goal of controlling symptoms and slowing or stopping 
disease progression, the intermediate goal with any inhaler 
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device is to ensure drug delivery at the right dose in the right 
place. In this respect, DPIs require higher inspiratory flows 
than pMDIs to ensure optimal particle size and delivery 
to the lower airways. Optimal particle size is 2–5 µm with 
smaller particles reaching the alveoli and larger particles 
settling in the mouth, both increasing systemic exposure 
and limiting clinical effectiveness (35). With DPI devices, 
the inhalation flow rate and the device-specific DPI intrinsic 
resistance must be perfectly balanced to ensure optimal 
particle size and airway deposition (36). For similar drug 
delivery and efficacy, low-resistance DPIs require a higher 
inhalation flow rate than medium- or low-resistance DPIs, 
leading to a wide range of device-specific flow rates needed 
for optimal drug delivery. In the currently available DPI 
devices, the required flow rates range from 37 L/min with 
the Handihaler® to 111 L/min with the Breezhaler® (37). 
In other words, either a DPI device-specific optimization of 
the inspiratory flow rate or the selection of an appropriate 
DPI inhaler for a given inspiratory flow is needed for 
optimal efficacy. In any case, adequate device-specific 
patient education is required but often neglected when 
prescribing a DPI in daily practice. 
Finally, in the present Asthma Survey, approximately 
22% of the patients with obstructive respiratory disease 
were considered having a mixed form of asthma and 
COPD, consistent with the recently characterized asthma-
COPD overlap syndrome (ACOS) (38,39). This figure is 
remarkably consistent with the reported prevalence rate 
of 15% to 25% of concurrent physician-diagnosed asthma 
and COPD (39-42). While a specific definition of ACOS 
is still lacking, due to poorly understood phenotypes and 
underlying mechanisms, it is characterized by persistent 
airflow limitation with several features usually associated 
with asthma and several others associated with COPD (39). 
It is well accepted that patients with features of both asthma 
and COPD experience more severe outcomes in terms of 
exacerbations, quality of life, decline in lung function, and 
mortality and use more healthcare resources than patients 
with either single disease alone (38,39,43). A stepwise 
diagnostic approach, as recently recommended (39), 
was obviously not part of the present survey, such that 
the true prevalence of ACOS cannot be inferred from 
the present findings. However, it is noteworthy that in a 
formerly dichotomic world in which asthma and COPD 
were separate clinical entities, practicing physicians clearly 
identify mixed forms of obstructive lung disease amongst 
their patients in similar proportions across linguistic 
regions. Further efforts should be undertaken to better 
understand whether these patients are appropriately 
diagnosed and get appropriate treatment.
The results of the present survey should be considered 
indicative of possible trends and serve as a basis for 
triggering further research. Among its strengths, the 
Asthma Survey collected real-world data under conditions 
of daily practice in a large sample of physicians. In addition, 
it is the first of its kind investigating differences between 
linguistic regions within a single country, highlighting the 
effects of cultural differences on daily medical practice. 
Heterogeneity across interviewers has been minimized 
by specific training prior to implementation. By nature, 
it reflects only the responses of physicians who accepted 
to participate, although the study sample was large. Most 
questions had a free text answering option. Although 
adjudication was done by a health care professional with 
experience in the field, room for subjective categorization 
still exists. Some questions asked were not aimed for in-
depth exploration of the selected areas interest, such that 
the interpretation of the results should be considered with 
caution. Nevertheless, these meta-level findings indicate 
possibly important differences in terms of perceptions 
and patient management across linguistic regions which 
deserve further understanding before engaging into large 
scale programs. Finally, there remains a possibility of 
unrecognized bias or confounding. As a trade-off between 
completeness and feasibility, the level of granularity of the 
physician characteristics was low and the survey did not 
collect any patient data, which is a limiting factor for more 
in-depth analyses. 
Conclusions
Real-world asthma management and inhaler use in daily 
practice differ between D-CH and W-CH and with regard 
to guidelines. Recognizing the specific difficulties related to 
pMDIs and DPIs, routine inhalation technique monitoring 
could be considerably improved in both regions. The 
reasons for higher pMDI preference in W-CH compared to 
D-CH deserve further research.
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The Asthma Survey Questionnaire
Patient education
1. Which of these practical aspects do you consider when prescribing an inhaled anti-asthmatic drug?
⬚ I train with my patient in my office;
⬚ My practice assistant trains the patient;
⬚ I write a note on the prescription (training by the pharmacist);
⬚ I hand out a flyer;
⬚ I indicate a link to a patient education video on the Internet;
⬚ I recommend reading the package insert;
⬚ Other: ______;
⬚ None.
2. Which supportive tools for inhalation technique training are missing in daily practice?
_______________________________________________________________________________________________________
_______________________________________________________________________________________________________
_______________________________________________________________________________________________________.
3. At which time intervals do you verify the technical appropriateness of your patients’ inhalation technique?
⬚ At the next consultation (time interval in weeks_____);
Thereafter every (time interval in weeks________);
⬚ Only in cases of insufficient asthma control;
⬚ Never.
Common errors when using inhalation devices
5. In patients using dry-powder inhalers (DPI), which are the most common errors encountered in daily practice?
DPI Frequent Now and then Rare Never
Wrong device actuation ⬚ ⬚ ⬚ ⬚
No expiration before inhalation ⬚ ⬚ ⬚ ⬚
Expiration in the actuated device ⬚ ⬚ ⬚ ⬚
Inhalation too slow and weak ⬚ ⬚ ⬚ ⬚
No breath-holding after inhalation ⬚ ⬚ ⬚ ⬚
Other___________________________ ⬚ ⬚ ⬚ ⬚
6. In patients using pressurized metered-dose inhalers (pMDI), which are the most common errors encountered in 
daily practice?
pMDI Frequent Now and then Rare Never
Wrong device preparation ⬚ ⬚ ⬚ ⬚
No expiration before inhalation ⬚ ⬚ ⬚ ⬚
Poor coordination between actuation and inhalation ⬚ ⬚ ⬚ ⬚
Inhalation too fast ⬚ ⬚ ⬚ ⬚
No breath-holding after inhalation ⬚ ⬚ ⬚ ⬚
Other___________________________ ⬚ ⬚ ⬚ ⬚
Supplementary
Physician preferences & behaviors
7. How many patients with an obstructive airway disease do you treat per week?
Number of patients with asthma: _________;
Number of patients with chronic obstructive pulmonary disease (COPD): _________;
Number of patients with a mixed form: _________________.
8. How many patients with an obstructive airway disease do you treat with a pMDI and how many with a DPI
______ % pMDI;
______ % DPI.
9. What are the main reasons for prescribing a pMDI?
_______________________________________________________________________________________________________
_______________________________________________________________________________________________________
_______________________________________________________________________________________________________.
10. What prior therapy was used in patients newly prescribed a fixed combination of an inhaled corticosteroid (ICS) 
and a long-acting beta agonist (LABA)?
⬚ A short-acting beta-agonist (SABA) only;
⬚ A leukotriene receptor antagonist (LTRA);
⬚ An ICS in monotherapy;
⬚ Another ICS+LABA combination;
⬚ Other: ____________.
Note: questions 4 and 11 were launch product related and not relevant to the general survey results.
